Clinico-epidemiological characteristics of men and women with a new diagnosis of chronic obstructive pulmonary disease: a database (SIDIAP) study by Montserrat i Capdevila, Josep et al.




of men and women with a new diagnosis 
of chronic obstructive pulmonary disease: 
a database (SIDIAP) study
Josep Montserrat‑Capdevila1,2,3,4* , Josep Ramon Marsal5, Marta Ortega2,4,6, Maria Teresa Castañ‑Abad2,4, 
Miquel Alsedà3,4,7, Ferran Barbé3,4,8,9 and Pere Godoy3,4,7,10
Abstract 
Background: The risk of developing Chronic Obstructive Pulmonary Disease (COPD), the associated comorbidities 
and response to bronchodilators might differ in men and women. The objective of this study was to determine the 
prevalence of COPD and the clinic‑epidemiological characteristics of primary care patients with COPD according to 
gender.
Methods: This is a cross‑sectional study using electronic healthcare records Catalonia (Spain), during the 
01/01/2012–31/12/2017 period. Patients from the SIDIAP database (System for the Development of Research in 
Primary Care) were included (5,800,000 patients registered in 279 primary care health centres). Clinic‑demographic 
characteristics, comorbidities and blood tests results were collected for each patient. Adjusted OR (ORa) with logistic 
regression methods were used to determine variables associated with men and women.
Results: From an initial sample of 800,899 people, 24,135 (3%) were considered COPD patients, and 22.9%were 
women. The most common risk factors in women were bronchiectasis (ORa = 20.5, SD = 19.5–21.6), age > 71 years 
(ORa = 18.8; SD = 17.3–20.5), cor pulmonale (ORa = 5.2; SD = 4.3–6.7) and lung cancer (ORa = 3.6, SD = 3.2–4.0). Men 
and women presented the same comorbidities, though the strength of association was different for each gender.
Conclusions: Patients suffering high comorbidity rates. Comorbidities are similar in men and women, although the 
strength of association varies according to gender. Women are more susceptible to the harmful effects of smoking 
and present a higher proportion of bronchiectasis and OSAS.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is 
a condition which causes high morbidity and mortal-
ity globally [1], and is currently considered one of the 
main public health issues [2]. While WHO estimates 
that there are 251 million people affected with COPD 
globally [2], the EPISCAN study (Epidemiologic Study 
of COPD in Spain) reported that in Spain over a mil-
lion and a half patients (73%) remained undiagnosed 
and untreated, and thus at higher risk of exacerbations 
and disease progression [2]. The main prevalence stud-
ies of COPD in the Spanish population are IBERPOC 
and EPISCAN. In 1997, IBERPOC showed a COPD 
prevalence of 9.1%, similar to the prevalence found a 
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decade later by EPISCAN (10.2%) [3]. COPD preva-
lence is highly heterogeneous, and it varies according 
to geographical location, the sample used and the defi-
nition of the disease. A systematic review on the prev-
alence of COPD in Europe found prevalence ranging 
between 2.1 and 26.1% in people over 40 years of age 
[4]. In the Vallès region of Catalonia, the prevalence of 
COPD using the criteria of the British Thoracic Soci-
ety was 7.2% (10.4% in men and 4.1% in women) [5]. A 
recent study conducted by our group in the population 
of Lleida (Catalonia) showed a prevalence of 14.5% 
(16.1% in men and 12.3% in women) [6].
COPD is associated with age, smoking [7] and cardi-
ovascular diseases [8]. The risk associated with COPD 
might be similar to that of widely accepted cardiovas-
cular factors such as hypertension and hypercholester-
olaemia [8]. Various studies have pointed at the high 
prevalence of cardiovascular diseases, diabetes, kidney 
failure and other diseases associated with COPD [9].
Patients with COPD attend frequently primary care 
and emergency services for problems related to comor-
bidities and exacerbation [10]. Consequently, primary 
care patients can be considered a suitable sample of 
the general population. Some studies indicate that risk 
patterns might be different in men and women [11, 
12], with different susceptibilities to develop COPD, 
associated comorbidities and response to bronchodi-
lators [11]. Understanding gender differences in risk 
factors and comorbidities related to COPD might con-
tribute to minimise their impact and improve the qual-
ity of life of these patients [13].
The objective of this study is to determine the preva-
lence of COPD and the clinico-epidemiological char-
acteristics by gender in patients who attended primary 
care centres in Catalonia during the 2012–2017 period.
Methods
Observational epidemiological study on the prevalence 
of COPD according to primary care consultations in 
Catalonia (Spain), with data originating from electron-
ical medical records from 01/01/2012 to 31/12/2017. 
The study aimed to discriminate clinico-epidemiolog-
ical characteristics between genders. Participants were 
eligible patients included in the SIDIAP (System for 
the Development of Research in Primary Care) [14], a 
database with anonymised information from 5,800,000 
patients assigned to 279 primary care centres of the 
Catalan Health Institute (approximately 80% of the 
Catalan population). In Catalonia, health professionals 
use ICD-10 to classify diseases in the electronic medi-
cal records (eCAP).
Population with a new diagnosis of COPD
Patients with COPD were identified for each year of the 
study period (2012–2017) using a diagnostic algorithm 
developed in previous studies that used similar data-
bases [15]: Following GOLD [16] guidelines, patients 
over 40 years of age diagnosed with COPD, emphysema 
or chronic bronchitis and with FEV1/FVC < 0.7 were 
included to perform spirometry. Patients diagnosed 
with COPD with spirometry result unknown, who 
were smokers/ex-smokers and received bronchodilator 
therapy (excluding treatment with cromoglycate and 
antileukotrienes), or who had never been smokers but 
received bronchodilator therapy (excluding treatment 
with cromoglycate and antileukotrienes) were also 
included. Patients not diagnosed with COPD but with 
spirometry results of FEV1/FVC < 0.7, not diagnosed 
nor treated for asthma were also included (see Fig. 1.).
Information on clinico-demographic characteristics, 
including history of smoking and alcohol consumption, 
comorbidities, blood tests results, bronchodilator ther-
apy and immunizations (influenza and pneumococcal) 
was obtained for each patient. Severity of COPD was 
evaluated in accordance to the most recent review of 
the 2018 GOLD Report [17].
The comorbidities (heart failure, ischemic heart dis-
ease, diabetes and prediabetes, chronic kidney disease, 
atrial fibrillation, anaemia, hypertension, dyslipidae-
mia, stroke and lung cancer) were obtained from the 
primary care electronic medical records and the hospi-
tal discharge minimum data set.
The study was approved by the Clinical Research Eth-
ics Committee of the Institut d’Investigació en Atenció 
Primària Jordi Gol of Barcelona (P13/063).
Statistical analysis
All data originated from the SIDIAP database. Patients 
were classified in two main groups (with and without 
characteristics suggestive of COPD) (Fig.  1). Data on 
the characteristics of the patients, diagnoses recorded 
by family doctors, and pharmacological treatment dis-
pensed in pharmacies (in Spain, medicines are sub-
sidized by the universal health care system) were 
collected. Variables were described with mean and 
standard deviation in case of continuous variables, and 
with absolute and relative frequencies in case of cat-
egorical variables. Differences between groups were 
analysed using Student’s t-test for continuous and 
Chi-squared test for categorical variables. Differences 
between groups were estimated calculating the differ-
ence of proportions and means. Logistic regression was 
used to estimate the crude and adjusted effects in both 
genders. The logistic regression models for men and 
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women were built using backward elimination, with a 
significance threshold of p < 0.1.
Results
A total of 24,135 (3%) out of the 800,899 people of the 
sample were considered to present clinical characteristics 
suggestive of COPD (Fig. 1); 22.9% were women, with an 
average age of 72 years (SD = 11). The highest proportion 
of patients with COPD was in 71 to 80  year age group 
(32.8%). The proportion of patients that were smok-
ers or ex-smokers was 66.8% in patients diagnosed with 
COPD, compared to 31.5% in patients without COPD 
(p < 0.001). In relation to alcohol consumption, 39.8% 
of patients with COPD admitted to a low, moderate or 
high risk drinking, compared to 31.1% of patients with 
no COPD (p < 0.001). With respect to severity (GOLD), 
49.1% patients with COPD were classified as moderate 
and 38.5% as severe. The average forced expiratory vol-
ume in one second (FEV1) in patients with COPD was 
57.7 (SD = 19.8). Table 1 shows the remaining variables.
Table  2 shows comorbidities and blood tests results 
(fibrinogen and C-reactive protein in peripheral blood) of 
patients with and without a COPD diagnosis. Up to 26.7% 
of patients with COPD had a diagnosis of type 2 diabe-
tes, 6.6% of prediabetes (capillary glycaemia between 110 
and 125 mg/dL), 59.1% presented hypertension (HT) and 
45.7% dyslipidaemia. Additionally, 13.1% had anaemia, 
11.8% atrial fibrillation, 8.8% ischaemic cardiomyopathy, 
11.7% chronic kidney disease, 9.4% heart failure, 8.1% 
had a history of stroke and 2.1% of lung cancer. Regarding 
blood tests results, mean fibrinogen in peripheral blood 
in patients with COPD was 407.2  mg/dL (SD = 105.7) 
and mean C-reactive protein (PCR) 15.3 (SD = 32.5). For 
all described comorbidities and blood tests results, statis-
tically significant differences were found in COPD versus 
non COPD patients.
Age is strongly associated to COPD in both genders, 
but the effect is higher in men. Moderate and high alco-
hol consumption in men represents 1.3 risk of COPD 
(p < 0.001). A history of smoking (smoker or ex-smoker) 
multiplies this risk by 3.5 (p < 0.01). Men with bronchi-
ectasis presented a risk 20.5 times higher of suffering 
from COPD (p < 0.001). Other frequent comorbidities in 
patients with COPD were anaemia (aOR = 1.2; p < 0.001) 
and ischaemic cardiomyopathy (aOR = 1.2; p < 0.001). 
Cor pulmonale and heart failure were also more preva-
lent amongst COPD patients (aOR = 5.3; p < 0.001 and 
aOR = 2.4; p < 0.001, respectively). Table  3 describes the 
crude and adjusted effect of comorbidities in men.
In women, the risk to develop COPD between 61 and 
70 years of age increased by 4.7, and by 14.5 from 80 years 
onwards (p < 0.001). While low alcohol consumption 
did not increase the risk to develop COPD, (aOR = 0.9; 
p = 0.22), moderate to high drinking increased the risk 
by 1.6 (p < 0.001). Bronchiectasis increased by 27.1 the 
risk to develop COPD (p < 0.001). History of smok-
ing increased almost five fold the risk to develop COPD 
(aOR = 4.7; p < 0.001). In women with COPD, comor-
bidities such as cor pulmonale and history of lung cancer 
were 3 times higher (aOR = 3.1; p < 0.001and aOR = 3.6; 
p < 0.001, respectively). Table  4 shows the remaining 
comorbidities.
Fig. 1 Flowchart of the study patients
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Table 1 Characteristics of SIDIAP patients at the beginning of the study
No
(n = 776,764; 97%)
Yes
(n = 24,135; 3%)
Dif Total
(n = 800,899; 100%)
p
N n (%) N n (%) N n (%)
Gender (female) 776,764 406,346 (52.3%) 24,135 5523 (22.9%) −29.4% 800,899 411,869 (51.4%)  < 0.001
Age 776,764 60 ± 14 24,135 72 ± 11 12 800,899 60 ± 14  < 0.001
Grouped Age 782,055 18,844 800,899  < 0.001
 41—50 254,121 (32.5%) 952 (5.1%) −27.4% 255,073 (31.8%)
 51—60 192,339 (24.6%) 2964 (15.7%) −8.9% 195,303 (24.4%)
 61—70 153,292 (19.6%) 5471 (29%) 9.4% 158,763 (19.8%)
 71—80 107,013 (13.7%) 6174 (32.8%) 19.1% 113,187 (14.1%)
 80 or more 75,290 (9.6%) 3283 (17.4%) 7.8% 78,573 (9.8%)
Smoking History (Y) 776,764 244,600 (31.5%) 24,135 16,117 (66.8%) 35.3% 800,899 260,717 (32.6%)  < 0.001
Alcohol Consumption 371,525 17,843 389,368  < 0.001
 No consumption 255,958 (68.9%) 10,734 (60.2%) −8.7% 266,692 (68.5%)
 Low Risk 107,170 (28.8%) 6374 (35.7%) 6.9% 113,544 (29.2%)
 Moderate Risk 8301 (2.2%) 725 (4.1%) 1.8% 9026 (2.3%)
 High Risk 96 (0%) 10 (0.1%) 0.0% 106 (0%)
Waist Circumference 66,004 101.6 ± 12.3 4183 105.8 ± 12.7 4.14 70,187 101.9 ± 12.4  < 0.001
 Missing 776,764 710,760 (91.5%) 24,135 19,952 (82.7%) −8.8% 800,899 730,712 (91.2%)  < 0.001
Grouped BMI 280,871 15,400 296,271 0.310
 Normal 59,635 (21.2%) 3306 (21.5%) 0.2% 62,941 (21.2%)
 Overweight 120,728 (43%) 6451 (41.9%) −1.1% 127,179 (42.9%)
 Obesity 100,508 (35.8%) 5643 (36.6%) 0.9% 106,151 (35.8%)
Gold grouped 9746 NA
 I 1205 (12.4%)
 II 4788 (49.1%)
 III–IV 3753 (38.5%)
Without bronchodilation
 FEV1/FVC 9213 59.6 ± 11.4
 FEV1 9054 57.7 ± 19.8
 FVC 8826 100.1 ± 201.6 FVC 8826
Table 2 Comorbidities and blood tests results in patients with and without COPD
COPD No
(n = 776,764; 97%)
Yes
(n = 24,135; 3%)
Dif Total
(n = 800,899; 100%)
p
N n (%) N n (%) N n (%)
DM2 (Y) 776,764 98,932 (12.7%) 24,135 6453 (26.7%) 14.0% 800,899 105,385 (13.2%)  < 0.001
Prediabetes (Y) 776,764 29,232 (3.8%) 24,135 1588 (6.6%) 2.8% 800,899 30,820 (3.8%)  < 0.001
Anaemia (Y) 776,764 60,875 (7.8%) 24,135 3160 (13.1%) 5.3% 800,899 64,035 (8%)  < 0.001
Ischaemic Cardiomyopathy (Y) 776,764 18,812 (2.4%) 24,135 2134 (8.8%) 6.4% 800,899 20,946 (2.6%)  < 0.001
Dyslipidaemia (Y) 776,764 250,256 (32.2%) 24,135 11,039 (45.7%) 13.5% 800,899 261,295 (32.6%)  < 0.001
AF (Y) 776,764 24,423 (3.1%) 24,135 2852 (11.8%) 8.7% 800,899 27,275 (3.4%)  < 0.001
Hypertension (Y) 776,764 262,190 (33.8%) 24,135 14,256 (59.1%) 25.3% 800,899 276,446 (34.5%)  < 0.001
Chronic kidney failure (Y) 776,764 29,259 (3.8%) 24,135 2823 (11.7%) 7.9% 800,899 32,082 (4%)  < 0.001
Heart Failure (Y) 776,764 13,253 (1.7%) 24,135 2672 (11.1%) 9.4% 800,899 15,925 (2%)  < 0.001
Stroke (Y) 776,764 22,330 (2.9%) 24,135 1944 (8.1%) 5.2% 800,899 24,274 (3%)  < 0.001
Lung Cancer (Y) 776,764 1740 (0.2%) 24,135 552 (2.3%) 2.1% 800,899 2292 (0.3%)  < 0.001
Fibrinogen 59,544 375.2 ± 94.3 3556 407.2 ± 105.7 32.01 63,100 377 ± 95.3  < 0.001
C‑reactive protein 56,406 8.3 ± 20.9 3367 15.3 ± 32.5 7.05 59,773 8.7 ± 21.7  < 0.001
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Discussion
The prevalence of COPD in the 800,899 population was 
3%. This prevalence is lower than that published in the 
EPISCAN (10.2%) and IBERPOC (9.1%) studies [3]. It is 
also lower than the prevalence indicated in other stud-
ies conducted in the Spanish population [16, 18], which 
showed COPD prevalences around 9%. The 3% preva-
lence obtained in this study might respond to under-
reporting in the primary care setting caused by mild 
symptomatology (most patients would be classified as 
GOLD stages1-2, with mMRC < 2 and CAT < 10) and 
under-recording of spirometry results. Experts believe 
that a significant number of patients remain undiag-
nosed [6]. The higher proportion of men than women 
(77.1% vs 22.9%, respectively) diagnosed with COPD is 
corroborated. However, the impact of shared risk fac-
tors such as age, smoking exposure and alcohol con-
sumption appears to be greater in women.
As previously reported [9, 19], comorbidities are com-
mon in patients with COPD (prediabetes and diabetes, 
ischaemic cardiomyopathy, dyslipidaemia, hypertension, 
heart failure, atrial fibrillation, history of stroke, lung 
cancer and chronic kidney disease). Mild reductions in 
airway flux in patients with COPD have been associated 
with higher risk of stroke, ischaemic cardiomyopathy and 
sudden cardiac death. It has been suggested that COPD 
exacerbations generate inflammatory processes which 
increase C-reactive protein, fibrinogen and endothelin-1 
Table 3 Univariate and multivariate analysis of the study variables in men
Men Descriptive Crude effect Adjusted effect
N n (%) OR CI (95%) p OR CI (95%) p
Age grouped 389,030
 41—50 134,104 (34.5%) 1 – 1 –
 51—60 97,416 (25%) 4.4 (4.1—4.8)  < 0.001 3.4 (3.1—3.7)  < 0.001
 61—70 76,965 (19.8%) 13.2 (12.2—14.3)  < 0.001 8.7 (8—9.4)  < 0.001
 71—80 51,763 (13.3%) 27.1 (25.1—29.3)  < 0.001 18.8 (17.3—20.5)  < 0.001
 80 or more 28,782 (7.4%) 34.2 (31.5—37.1)  < 0.001 29.1 (26.6—31.8)  < 0.001
Smoking 389,030 173,001 (44.5%) 4.1 (4—4.3)  < 0.001 3.5 (3.4—3.6)  < 0.001
Bronchiectasis 389,030 10,479 (2.7%) 31.3 (30—32.7)  < 0.001 20.5 (19.5—21.6)  < 0.001
Cor Pulmonale 389,030 451 (0.1%) 21.0 (17.4—25.2)  < 0.001 5.3 (4.3—6.7)  < 0.001
Lung Cancer 389,030 1790 (0.5%) 8.2 (7.4—9.1)  < 0.001 3.6 (3.2—4)  < 0.001
Heart Failure 389,030 7155 (1.8%) 7.9 (7.4—8.3)  < 0.001 2.4 (2.3—2.6)  < 0.001
OSAS 389,030 8767 (2.3%) 2.9 (2.7—3.1)  < 0.001 1.7 (1.6—1.9)  < 0.001
Osteopathy 389,030 3228 (0.8%) 4.4 (4.1—4.9)  < 0.001 1.6 (1.5—1.8)  < 0.001
Alcohol Consumption Risk Rate 389,030
 No intake 94,120 (24.2%) 1  < 0.001 1  < 0.001
 Low 80,222 (20.6%) 0.9 (0.9—0.9)  < 0.001 0.9 (0.9—1)  < 0.001
 Moderate or High 7855 (2%) 1.1 (1—1.2) 0.006 1.3 (1.1—1.4)  < 0.001
 NA 206,833 (53.2%) 0.3 (0.3—0.3)  < 0.001 0.7 (0.7—0.8)  < 0.001
Depression 389,030 30,568 (7.9%) 1.4 (1.4—1.5)  < 0.001 1.3 (1.2—1.3)  < 0.001
Ischaemic Cardiomyopathy 389,030 14,546 (3.7%) 3.1 (2.9—3.3)  < 0.001 1.2 (1.1—1.3)  < 0.001
AF 389,030 13,974 (3.6%) 4.1 (3.9—4.3)  < 0.001 1.2 (1.1—1.3)  < 0.001
Anaemia 389,030 17,209 (4.4%) 3.3 (3.2—3.5)  < 0.001 1.2 (1.1—1.2)  < 0.001
Chronic kidney failure 389,030 16,268 (4.2%) 3.5 (3.3—3.6)  < 0.001 1.1 (1—1.2) 0.001
Dyslipidaemia 389,030 122,087 (31.4%) 1.9 (1.8—1.9)  < 0.001 1.0 (0.9—1) 0.009
Hypertension 389,030 131,174 (33.7%) 2.9 (2.8—3)  < 0.001 0.9 (0.9—1) 0.004
DM2 389,030 58,219 (15%) 2.3 (2.3—2.4)  < 0.001 0.9 (0.9—1)  < 0.001
Grouped BMI 389,030
 Normal 25,352 (6.5%) 1 – 1 –  < 0.001
 Overweight 67,457 (17.3%) 0.8 (0.7—0.8)  < 0.001 0.8 (0.7—0.8)  < 0.001
 Obesity 47,140 (12.1%) 0.9 (0.8—0.9)  < 0.001 0.9 (0.8—0.9)  < 0.001
 NA 249,081 (64%) 0.2 (0.2—0.2)  < 0.001 0.7 (0.7—0.8)  < 0.001
ROC Curve 0.896 (0.89—0.9)
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vasoconstrictor peptide in peripheral blood. These fac-
tors participate in the genesis of atherosclerosis [20], the 
decline in vascular function and endothelial dysfunc-
tion, causing cardiovascular complications. Another 
study conducted in a Spanish population found similar 
prevalences of hypertension (43%), dyslipidaemia (33%) 
and diabetes (16%) [21]. Additionally, 13.3% of COPD 
patients in our study suffered from anaemia, similarly 
to other series reporting percentages over 10% [22, 23]. 
Anaemia reduces exercise capacity. While the pathophys-
iology of anaemia in COPD is still debated, some authors 
have suggested that the inflammation of COPD mediated 
by INF-a, IL-1, IL-6 and IFN-gamma induces changes 
in iron metabolism, reducing the intestinal absorption 
of this metal and consequently affecting haematopoiesis 
[24]. Studies show an increase in the proportion of anae-
mia in older and more severe (GOLD) cases of COPD. 
For instance, Watz et  al. reported a 14% prevalence of 
anaemia in patients with very severe COPD (GOLD 4) 
[25]. Since most COPD patients have a long history of 
smoking, lung cancer is more frequent in this group of 
patients. One study showed that cancer was the cause of 
death in 16.1% of patients with COPD, with lung cancer 
being the most common [26]. As previously described, 
bronchiectasis are a significant risk factor of COPD [27]
Table 4 Univariate and multivariate analysis of the study variables in women
Women Descriptive Crude effect Adjusted effect
N n (%) OR CI (95%) p OR CI (95%) p
Age grouped 411,869
41–50 120,969 (29.4%) 1 – 1 –
51–60 97,887 (23.8%) 2.8 (2.5–3.1)  < 0.001 2.5 (2.2–2.8)  < 0.001
61–70 81,798 (19.9%) 4.2 (3.8–4.7)  < 0.001 4.7 (4.1–5.3)  < 0.001
71–80 61,424 (14.9%) 7.1 (6.3–7.9)  < 0.001 8.9 (7.8–10.1)  < 0.001
80 or more 49,791 (12.1%) 11.0 (9.8–12.2)  < 0.001 14.5 (12.7–16.6)  < 0.001
Smoking 411,869 89,687 (21.8%) 2.4 (2.3–2.5)  < 0.001 4.7 (4.4–5)  < 0.001
Lung Cancer 411,869 502 (0.1%) 5.9 (4.2–8.2)  < 0.001 3.6 (2.5–5.2)  < 0.001
Bronchiectasis 411,869 4994 (1.2%) 32.6 (30.4–35)  < 0.001 27.1 (25–29.3)  < 0.001
Lung Cancer 411,869 502 (0.1%) 5.9 (4.2–8.2)  < 0.001 3.6 (2.5–5.2)  < 0.001
Cor Pulmonale 411,869 505 (0.1%) 13.2 (10.3–16.9)  < 0.001 3.1 (2.3–4.1)  < 0.001
Heart Failure 411,869 8770 (2.1%) 8.2 (7.6–8.9)  < 0.001 3.0 (2.7–3.3)  < 0.001
OSAS 411,869 2884 (0.7%) 4.4 (3.7–5.2)  < 0.001 2.2 (1.8–2.6)  < 0.001
Alcohol Consumption Risk Rate 411,869
No intake 172,572 (41.9%) 1  < 0.001 1  < 0.001
Low 33,322 (8.1%) 0.9 (0.8–1) 0.002 0.9 (0.9–1) 0.220
Moderate or High 1277 (0.3%) 1.9 (1.4–2.5)  < 0.001 1.6 (1.2–2.3) 0.005
NA 204,698 (49.7%) 0.4 (0.4–0.4)  < 0.001 0.8 (0.7–0.8)  < 0.001
Ischaemic Cardiomyopathy (no AMI) 411,869 6400 (1.6%) 3.7 (3.3–4.1)  < 0.001 1.3 (1.1–1.5)  < 0.001
Osteopathy 411,869 46,798 (11.4%) 2.2 (2.1–2.4)  < 0.001 1.3 (1.2–1.4)  < 0.001
Depression 411,869 76,067 (18.5%) 1.6 (1.5–1.7)  < 0.001 1.3 (1.2–1.3)  < 0.001
Hypertension 411,869 145,272 (35.3%) 3.0 (2.8–3.1)  < 0.001 1.2 (1.1–1.3)  < 0.001
DM2 411,869 47,166 (11.5%) 2.3 (2.1–2.4)  < 0.001 1.1 (1–1.2) 0.008
Anaemia 411,869 46,826 (11.4%) 1.5 (1.4–1.6)  < 0.001 1.1 (1–1.2) 0.018
FA 411,869 13,301 (3.2%) 4.0 (3.7–4.3)  < 0.001 1.1 (1–1.3) 0.014
Chronic kidney failure 411,869 15,814 (3.8%) 3.0 (2.8–3.3)  < 0.001 1.1 (1–1.2) 0.108
Dyslipidaemia 411,869 139,208 (33.8%) 1.8 (1.7–1.9)  < 0.001 1.0 (0.9–1) 0.336
Grouped BMI 411,869
Normal 37,589 (9.1%) 1 – 1.0 –
Overweight 59,722 (14.5%) 0.9 (0.8–1) 0.003 0.8 (0.7–0.9)  < 0.001
Obesity 59,011 (14.3%) 1.2 (1.1–1.3)  < 0.001 1.0 (0.9–1.1) 0.461
NA 255,547 (62%) 0.4 (0.4–0.5)  < 0.001 0.9 (0.8–1) 0.099
ROC Curve 0.863 (0.86–0.87)
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COPD is more prevalent in older men. Prevalence is 
higher in men between 71 and 80 and over 80 years of age 
(ORa = 18.8, p < 0.001 and ORa = 29.1, p < 0.001), respec-
tively. Some research indicates that irreversible bronchial 
obstruction and decline of the FEV1 increase with age 
[28]. Another risk factor is moderate-high alcohol con-
sumption, which is 1.3 higher in men with a diagnosis of 
COPD compared to those not diagnosed with this con-
dition. Interestingly, in men with a diagnosis of COPD, 
moderate to high alcohol consumption is associated 
with higher use of tobacco [19]. In this respect, the asso-
ciation between smoking and COPD [7] has long been 
recognized, and men with a history of smoking have are 
3.5 times more likely to have COPD. The most frequent 
comorbidities in men with COPD are cor pulmonale (5.3 
times more prevalent in men with than without COPD) 
and heart failure (2.4 times more common in males with 
COPD). Our study has shown a lower ORa than the study 
by Villar et al., which reported an ORa of 4.5 of heart fail-
ure in patients with COPD [29]. Pathophysiologically, 
the use of systemic corticosteroids to treat exacerbations 
in moderate and severe COPD can generate fluid reten-
tion and over time, this increase in blood volume might 
cause heart failure [20]. Additionally, treatment with 
beta-adrenergic bronchodilators might cause tachycar-
dia, an increase in myocardial oxygen consumption and 
thus aggravation of symptoms in patients with heart fail-
ure [30]. Anaemia was also 1.2 times more frequent in 
patients with COPD.
Older age is also a risk factor for COPD in women, and 
prevalence is 9 times higher in women between 71 and 
80 years of age (ORa = 8.8; p < 0.001). Women with mod-
erate to high alcohol consumption are at higher risk than 
men of COPD (ORa = 1.6 vs. ORa = 1.3, respectively). 
Similarly, the risk in women with a history of smoking 
is also higher than in men (risk 4.7 vs. 3.5 times higher 
to present COPD, respectively). Some authors have sug-
gested that the higher risk of women to develop COPD 
can be explained by their higher susceptibility to the 
effects of smoking, their longer exposure to indoor pol-
lution, and by anatomic and hormonal characteristics 
[12, 31]. The risk of presenting bronchiectasis was higher 
in women with COPD (ORa = 27.1) than in their male 
counterparts (ORa = 20.5). This finding has also been 
described by Oliveira et al. [27], which analysed a cohort 
of 20,047 patients with bronchiectasis from 36 health 
centres in Spain, and concluded that 54.9% were women. 
The most common causes for bronchiectasis were sys-
temic, idiopathic and post-infectious diseases. Other 
comorbidities such as obstructive sleep apnoea syn-
drome (OSAS), are also more common in women than 
in men (twofold increase in prevalence in women with 
COPD, compared to 1.7 in men with COPD). The ORc 
for diabetes was 2.3 for male and female COPD patients. 
This risk is attributed to the hyperglycaemia caused by 
the treatment of moderate and severe COPD exacerba-
tions with systemic corticosteroids, which over time 
might cause diabetes in a subgroup of COPD patients 
[32]. However, this risk decreased in the multivariate 
analysis.
Limitations
Since the information has been obtained from the SID-
IAP database (data that originate from the electronic 
medical records), under-recording should be consid-
ered. An additional limitation to consider is the fact that 
no spirometric curves of patients included in the study 
have been analysed. Also, in a prevalence study the asso-
ciations might not be causal. For instance, comorbidi-
ties such as bronchiectasis can be risk factors for COPD, 
whereas associated diseases such as cor pulmonale could 
be the result of this condition. Furthermore, the large 
population sample might produce statistically significant 
differences with no clinical relevance. The classification 
of the database follows the algorithm proposed by Barre-
cheguren et al. [15], and thus false positives and false neg-
atives need to be considered. Another limitation when 
working with a large database would be under-reporting 
some data from the medical records of patients, as the 
FEV1/FVC case. In order to minize this fact, Barreche-
guren et al. [15] algorithm was used in order to be able 
to include higher number of patients and to ensure high 
statistical power of the study.
Conclusion
COPD prevalence in the SIDIAP cohort is lower than 
expected (3%), probably due to under-recording of clini-
cal information in primary care medical records. Patients 
suffering from COPD present high comorbidity rates. 
Although in general risk factors are the same in both gen-
ders, women appear to be more susceptible to harmful 
exposures such as smoking and present a higher propor-
tion of bronchiectasis and OSAS. Understanding asso-
ciated comorbidities is crucial for an integral approach 
to COPD. Further research in similar cohorts would be 
required to provide new evidence on the prevalence of 
COPD as well to determine the incidence of disease exac-
erbation based on clinical-epidemiological features.
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